SCHEMBL13756903

SCHEMBL13756903

O=C1NC(c2ccc(Nc3ncc4c(n3)N(c3cc(F)c(CN5CCOCC5)c(F)c3)CC4)cc2)CN2CCCCC12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 4/20 0.39
EGFR P00533 3/20 0.37
CSF1R P07333 3/20 0.37
JAK2 O60674 1/20 0.37
BRD4 O60885 1/20 0.37
CDK4 P11802 6/20 0.36
CCND1 P24385 6/20 0.36
CCNT1 O60563 4/20 0.36
CDK9 P50750 4/20 0.36
CCND3 P30281 4/20 0.36
CDK6 Q00534 2/20 0.36
LRRK2 Q5S007 3/20 0.36
BTK Q06187 1/20 0.35
CCNB2 O95067 2/20 0.35
CDK1 P06493 2/20 0.35
CCNB1 P14635 2/20 0.35
CCND2 P30279 2/20 0.35
CCNB3 Q8WWL7 2/20 0.35
CCNE2 O96020 1/20 0.35
CCNA2 P20248 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13746448 0.85 RPS6KA3 (0.45) STAT6JAK2BRD4CDK4CCND1
SCHEMBL13756805 0.76 STAT6 (0.47) STAT6EGFRCSF1RLRRK2CDK2
SCHEMBL13756783 0.74 STAT6 (0.39) STAT6EGFRCSF1RJAK2BRD4
SCHEMBL3433530 0.74 RPS6KA3 (0.45) STAT6JAK2BRD4CDK4CCND1
SCHEMBL13756835 0.73 JAK1 (0.49) STAT6CSF1RJAK2CDK4CDK6
SCHEMBL13756718 0.73 SYK (0.43) STAT6EGFRCSF1RJAK2BRD4
SCHEMBL13756778 0.73 STAT6 (0.39) STAT6JAK2BRD4SYKNPC1
SCHEMBL13756789 0.73 STAT6 (0.42) STAT6EGFRBTKSYKNPC1
SCHEMBL13756772 0.73 LRRK2 (0.48) STAT6JAK2BRD4LRRK2
SCHEMBL13756788 0.73 STAT6 (0.36) STAT6EGFRJAK2BRD4CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 STAT6 601/4885EGFR 109/4885CSF1R 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.